High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard α-interferon and ribavirin

20Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Ribavirin is associated with haemolytic anaemia, Antioxidants have been reported to decrease severity of this anaemia. Aim: To determine effect of vitamin E supplementation on ribavirin-associated haemolysis in chronic hepatitis C treated with standard α-interferon and ribavirin. Methods: Fifty-one naive chronic hepatitis C patients were randomized to receive either α-interferon/ribavirin therapy (control) or therapy plus vitamin E 800 IU b.d. with 24-week follow-up. Alanine aminotransferase ALT, haemoglobin and reticulocyte percentage were monitored. Symptoms and health-related quality of life were also monitored at each visit. Results: Forty-seven subjects were treated (27 vitamin E /20 controls). Thirteen withdrew because of adverse effects or non-compliance. Groups were similar in demographics, genotype and baseline lab indices. Comparison with baseline, treatment and follow-up values showed a significant haemoglobin and ALT reduction in both groups. There was no significant difference in haemoglobin and reticulocyte percentage between groups. Sustained viral response was not significantly different between vitamin E (11/18) and control (6/16) groups. Three patients required ribavirin dose-reduction in the vitamin E group compared with two controls. Health-related quality of life during and end-of-treatment was not different between groups. Conclusions: Vitamin E supplementation alone during standard α-interferon and ribavirin therapy does not appear to diminish ribavirin-associated haemolysis.

Cite

CITATION STYLE

APA

Saeian, K., Bajaj, J. S., Franco, J., Knox, J. F., Daniel, J., Peine, C., … Ho, S. (2004). High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard α-interferon and ribavirin. Alimentary Pharmacology and Therapeutics, 20(10), 1189–1193. https://doi.org/10.1111/j.1365-2036.2004.02260.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free